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RNA-seq is the next-generation sequencing technology for gene expression and while
many tools have been developed to assess differential expression, most focus on gene-level
statistics. Gene-level statistics implicitly ignore any dependence among genes. In order to
directly incorporate correlation into testing for differential expression, genes are sorted into
networks using Ingenuity Pathway Analysis (IPA) and the gene expression of each network is
modeled using Generalized Estimating Equations (GEE). Since the gene network data often
exhibits correlation structures containing positive and negative values, a new intermediate
correlation structure is developed.

This structure provides a compromise between an

exchangeable (one parameter for all gene pairs) and unstructured (one parameter for each gene
pair). A log-linear regression model and Wald test are proposed for differentially expressed
gene networks via hypothesis testing. Additionally, a statistical test to determine whether a
given gene network is independent or correlated is given. Numerical studies via simulations
of correlated negative binomial data are used to compare different correlation structures of
GEE based on type I error and statistical power. Also, these simulations are used to benchmark
the test of gene network independence.

Models that incorporate correlation into estimation

are able to conserve type I error, while independent correlation structures do not. Positive
correlations unaccounted for in the independence model lead to increases in type I error, while
negative correlations lead to decreases in type I error. Power between models is roughly the
same. Goodness-of-fit tests reveal that the correlated negative binomial data is a better fit to
the actual data than the univariate negative binomial distribution. Data analysis consisted of
two stages: (i) analyzing gene networks with GEE to find differentially expressed networks
and (ii) performing a single gene analysis on these differentially expressed networks. A RNAseq dataset from the Cancer Genome Atlas (TCGA) of breast cancer patients was analyzed,
adjusting for relevant clinical covariates. The top genes from each network are scrutinized for
biological relevance using PubMed searches and other knowledge-based databases such as
OMIM. These genes show a mix of genes with no citations to genes with many citations. This
implies that this data analysis approach finds both novel genes as well as genes that have been
well-studied in the field of breast cancer research.
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BACKGROUND
Literature Review
Cancer is second leading cause of death in the United States and is expected to overtake
heart disease as the leading cause of death in the next few years (Rl, Kd, & Jemal,
2015). Surveillance Epidemiology and End Results (SEER) estimates that 1,658,370 people
will be diagnosed with cancer and 589,430 people will die from cancer in 2015; these deaths
will account for 25% of the total deaths in the United States (Howlader et al., 2014). Moreover,
cancer survival has increased by about 4% in the past two decades.
Cancer is a group of diseases that, if left untreated, are fatal for many patients. For
example, patients with breast cancer who are not treated have a median survival time of 2.7
years (5-year survival rate: 18%, 10-year survival rate: 3.6%) (R. H. Riffenburgh & Johnstone,
2001; Robert H Riffenburgh, 2000).

Many of these tumors can be treated effectively,

improving survival and in some cases, enabling patients to manage their cancer throughout
their lives (Howlader et al., 2014). However, other tumors cannot be managed with current
therapies and will ultimately lead to death. Prevention efforts such as mammograms (x-ray
pictures of the breast) can identify a tumor at an earlier stage, giving greater lead time, but
provide no reduction in mortality rates (Miller et al., 2014). To reduce mortality rates, there is
a need to understand the molecular etiologies of tumors.
RNA-seqencing (RNA-seq) is a next-generation sequencing technology that measures
the expression of genes with great accuracy and with genome-wide coverage. Analyzing
RNA-seq data is typically done for each gene separately using a statistical test or regression
model with a multiple testing adjustment such as the false discovery rate (FDR). This
1

procedure identifies genes that are differentially expressed across two or more populations
(such as tumor vs normal). Both experimental and numerical studies have shown these single
gene approaches have low sensitivity (~50%), implying that many genes are missed. To
improve sensitivity, networks, instead of single genes, will need to be analyzed.
Oncogenesis (the development of cancer) is largely the result of activated oncogenes
(cancer-causing genes) and deactivated tumor suppressor genes (Weinberg, 2013). The
interplay between these genes regulate cell proliferation in healthy humans, but when
homeostasis is disrupted the result is the creation of a tumor. As the cancer progresses,
additional genetic damage is acquired through mutations or epigenetic silencing that alters
gene expression (Nussbaum, McInnes, & Willard, 2015). Identifying genes which have their
expression altered during both the initiation and progression of cancer is both clinically
important and biologically relevant. Discovering these differentially expressed genes helps to
generate hypotheses about tumor genetics, providing evidence and the first step for the
development of future clinical interventions.
A number of different genes have been identified in different types of cancers. Cancer
genes can be specific to a cancer type or shared among many cancer types. As of 2013, a total
of 125 genes (either oncogenes or tumor suppressor genes) have been found (Vogelstein et al.,
2013). Additional experiments of gene finding have yielded similar genes in different tumors,
leading the authors to the conclusion that most of the genes in cancer have been
found. However, estimates of explained genetic variation argue that there may be much to
learn in cancer genetics. For example, genes found in breast cancer have only explained 12.5%
of the total genetic variation, implying there is still much to discover (So, Gui, Cherny, &
2

Sham, 2011). One possible reason for the lack of predictiveness of genetics is that the statistical
methods for determining important genes do not accurately portray the biology. Specifically,
in gene expression studies, genes are assumed to be the unit of analysis and each gene is
independently tested, ignoring any relationship among genes. The importance of gene clusters
is well-established, yet this assumption of independence, and a focus on individual genes,
persists.
Single gene analyses in RNA-seq differential expression fall into two categories: count
modeling and variance modeling.

The goal of single gene methods is to address the

phenomenon that different genes have different variances (of gene expression). Implicitly,
these single gene analyses assume statistical independence among genes, reducing this
covariance to zero. Count modeling focuses on modeling the raw counts of RNA fragments
measured to quantify gene expression for each gene in an RNA-seq experiment. While the
Poisson distribution is the most natural for count data, it only accounts for technical variation
(one sample repeated multiple times) (Marioni, Mason, Mane, Stephens, & Gilad, 2008). To
allow for biological variation (multiple patients as opposed to one patient repeated multiple
times), a negative binomial distribution is used because it allows for “overdispersion” or the
modeling of extra variation beyond that predicted by the Poisson distribution (McCarthy,
Chen, & Smyth, 2012a). In the negative binomial model, the overdispersion parameter, φ ,
controls the amount of variance beyond Poisson through the equation V= µ + φµ 2 ( µ is the
mean).

3

Competing methods for count modeling mostly differ in how they estimate this
dispersion parameter. For example, trending dispersion as a function of the mean (Love,
Huber, & Anders, 2014a), squeezing between the gene-specific and common (pooling across
genes) dispersion (McCarthy et al., 2012a). Additionally, methods focus on other complicating
data features such as outliers (Zhou, Lindsay, & Robinson, 2014) or excess zeroes (Van De
Wiel et al., 2013). Variance modeling strategies differ from count modeling in that variance
modeling ignores the correct distribution of the count data in favor of modeling the meanvariance relationship (Law, Chen, Shi, & Smyth, 2014). The idea here is to use established
methods in microarray data analysis for RNA-seq. Additionally, the normal distribution,
which is used heavily in microarrays, is much easier to work with and is better understood than
a negative binomial model. However, these methods have not considered addressing gene
covariance in the context of RNA-seq which could contribute a nontrivial amount to the
variance estimation. This represents an opportunity to develop methods for addressing gene
covariance in RNA-seq data analyses.
Methods that incorporate intergene correlation (broadly labeled gene set analyses) can
improve detection of differentially expressed genes. For single gene analyses, sensitivities
ranges from 50 % – 65%, when data is simulated under an independence assumption (Love,
Huber, & Anders, 2014b; Zhou et al., 2014). Current simulation studies have shown that when
there is unaccounted intergene correlation there is a greater number of false positives among
the most significant genes (H. Zhang, Xu, Jiang, Hu, & Luo, 2015). Gene set analyses can
improve the sensitivity and also the interpretability of these analyses. Gene set analyses can
be partitioned into two types of tests based on the null hypothesis that they test: self-contained
4

and competitive.

Self-contained tests compare if a collection of genes is differentially

expressed between two groups (e.g. tumor versus normal), while a competitive test compares
a collection of genes against all other genes not in that set (Goeman, Bu, Zurich, & Zu, 2007).
An example of a competitive test is enrichment testing, where single gene test statistics are
aggregated, and an example of a self-contained test is network analysis.
Addressing intergene correlations has been used extensively in differential expression
analyses of microarrays. One of these competitive gene set approaches is gene set enrichment
analysis (GSEA) (Tamayo, Steinhardt, Liberzon, & Mesirov, 2012), (Subramanian et al.,
2005). GSEA addresses correlation among genes by organizing them into sets (such as through
gene ontology, statistical clusters, or pathways from previous biological knowledge) and
determines enrichment scores. Enrichment is a procedure which aggregates test statistics from
a single gene analysis into one global statistic (through some mathematical function) to
determine if grouping genes improves detection of differential expression. Correlation among
genes is taken into account using resampling procedures and develops an empirical null
distribution for hypothesis testing (Tamayo et al., 2012). GSEA splits one formal statistical
modeling task into two stages. This is similar to a situation in longitudinal data analysis where
repeated measurements are assumed (incorrectly) to be independent and then adjusted for posthoc (Hardin & Hilbe, 2002). This discretization into two stages results in an efficiency (the
rate of convergence to the standard error) loss when estimating standard errors and suggests
that directly assessing correlation in one statistical model can improve the detection of
differentially expressed genes by estimating standard errors that are closer to the true standard
errors. Efficiency is important in genomics because the sample size is likely never sufficient
5

and thus, greater efficiency will translate to greater statistical power and better detection of
differentially expressed genes.
A better approach is to organize genes into gene networks and address correlation
among genes within each network. Multivariate (multiple response) regression models can be
useful in this context because they are able to model gene expression levels of multiple genes
in one regression, which allows for a direct assessment of the correlation among these genes.
The methods of multivariate regression models vary based on the distribution of the response.
For example, a multivariate linear model can be used with the assumption that the areas are
distributed according to multivariate normal (Huang & Lin, 2013). This type of model has
shown improvements in sensitivity over the GSEA procedure when analyzing microarray data
and the authors argue that this translates to RNA-seq. Currently, no methods are available for
the assumption of a multivariate negative binomial distribution (for count data in RNA-seq).
This is potentially important because many of the single gene approaches rely on a negative
binomial assumption. Mimicking this assumption for multivariate regressions seems logical
for increasing sensitivity in RNA-seq analyses.
Public Health Significance
Cancer is a major public health threat in the United States and learning more about the
genetics of cancer is the first step to better treatment and management of the disease. Current
RNA-seq analyses suffer from low sensitivity, preventing researchers from identifying
important genes. Multivariate regression allows for direct assessments of correlation among
genes and provides a useful framework for more sophisticated RNA-seq analyses. While
multivariate regression for count data has been used in longitudinal analysis for clinical trials
6

data, it has not been recognized for their usefulness in RNA-seq analyses (Solis-Trapala &
Farewell, 2005). Recognizing that longitudinal approaches can be repurposed for RNA-seq
opens up many possibilities to improve sensitivity in RNA-seq analyses. Furthermore, the
creation of more sensitive RNA-seq approaches can be applied broadly across all different
cancer types. Using large databases, this allows for relatively quick scans to find important
genes across a number of different cancers. By focusing on increasing sensitivity for a general
method, a number of cancer genes can be discovered which have been missed by previous
methodologies.
Specific Aims
Despite the enormous investment in cancer genomics research, the majority of
somatically disrupted genes are unknown. One of the reasons that researchers are unable to
discover these genes is because statistical methods for locating these genes ignores any
covariance between the gene expressions for a given pair of genes in a given population (e.g.
tumor samples). The consequence of using these statistical models is that they incorrectly
estimate the variance of gene expression, leading to decreased sensitivity and specificity.
Relaxing this assumption, using a network of genes instead of single genes, I assume that genes
are correlated within a network, but are (approximately) independent between networks.
Developing a statistical model that directly incorporates this correlation among genes will
likely increase specificity and sensitivity, compared to single gene methods, and improve the
detection of these unknown genes being disrupted in cancers.
I propose that using gene networks, instead of single genes, and leveraging prior biological
information in these networks via a multivariate regression model will enable the discovery of
7

new cancer genes. This is because a gene network approach will have greater sensitivity (while
controlling specificity) than a single gene approach. I will develop a multivariate regression
model (multiple responses) in the context of RNA-sequencing (RNA-seq) data, modeling the
gene expression of each individual gene in a network as the response with tumor status (tumor
vs. normal tissue) as the primary exposure. I expect statistical methods that integrate gene
dependence into analyses will have greater statistical power in the presence of gene
dependence and equivalent statistical power among genes with no dependence.
Aim 1: Develop an algorithm for identifying differentially expressed gene networks
A multivariate (multiple responses) regression model will be developed for gene networks in
RNA-seq count data. This method will extend the univariate negative binomial model to
enable an entire network of genes to be analyzed in one regression analysis while incorporating
correlations among different genes in a gene network. This proposed method is expected to
improve the sensitivity while controlling specificity at current levels.
Aim 2: Empirically evaluate the proposed algorithm with current single-gene approaches
Simulations will be conducted to assess the sensitivity and specificity of the proposed
algorithm with single-gene approaches in the presence (absence) of correlation among genes.
This will help to identify the strengths and weaknesses of various approaches and help to
improve our methods.
Aim 3: Identify differentially expressed gene networks and genes in primary breast
tumors
RNA-seq data of primary breast tumors will be downloaded from the Cancer Genome Atlas
(TCGA) and genes will be organized into networks using Ingenuity Pathway Analysis (IPA),
8

a literature-driven database. These networks will be analyzed using the algorithm in Aim 1
and significance will be assessed at the false discovery rate (FDR) of 0.05. Although this
analysis focuses on primary breast tumors, it is applicable to all other tumor types in TCGA
(as well as for RNA-seq data for other diseases). The newly identified genes by this method
will be carefully scrutinized and their biological significances will be assessed.
I propose a new statistical method to locate differentially expressed gene networks from
RNA-seq data. Using prior biological information and gene structure, I expect the proposed
method will have greater statistical power than single gene approaches. This implies that
analyzing data with a gene network approach will identify new cancer genes to explain more
of the total genetic variation in different cancers. The results will add to the current knowledge
of disrupted genes in different cancers, providing a foundation for the development of new
treatments.
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JOURNAL ARTICLE
Incorporating Correlation Structure into the Analysis of RNA-seq Data
Statistical Applications in Genetics and Molecular Biology
Author List: Aschenbrenner, Andrew; Loose, David; Mullen, Patricia Dolan; Fu, Yun-Xin
Abstract:
RNA-sequencing (RNA-seq) experiments are becoming the standard for gene
expression studies. Typically, analyzing these datasets involves using a count distribution such
as negative binomial (NB) with genewise hypothesis testing. However, these approaches
ignore the correlation among genes. Simulation studies show that ignoring correlation among
genes results in a lack of conservation of type I error; greater error for positive correlation and
less error for negative correlation. Additionally, we present a general framework for finding
correlation structures with varying degrees of complexity, creating a compromise between
exchangeable and unstructured correlation structures. This allows researchers to customize
the estimated correlation structure that is incorporated into the data analysis and reducing the
chance of a misspecified correlation structure.
Introduction
RNA-sequencing (RNA-seq) has proven to be a useful tool for investigations of gene
expression due to its high-resolution view of the entire transcriptome.

Each RNA-seq

experiment follows a general workflow: random fragmentation of mRNA from samples,
reverse transcription of fragmented mRNAs to create complementary DNAs (cDNAs), PCR
amplification and sequencing of cDNAs to a list of subsequences or reads, mapping of these
reads to genes via a reference genome, and creation of a flat-file table that contains counts for
10

each gene, for each sample (Garber, Grabherr, Guttman, & Trapnell, 2011). Each count in a
given gene correlates with that gene’s expression level. This resulting table of gene expression
counts is often the subject of downstream statistical analyses.
Initially, data analysis focused on individual gene expression. For example, several
count distributions have been used to model the gene expression (due to gene expression data
is presented as a matrix of counts), for example using the Poisson (Mortazavi, Williams,
McCue, Schaeffer, & Wold, 2008), (Marioni et al., 2008) or the negative binomial distribution
(McCarthy, Chen, & Smyth, 2012b), (Love et al., 2014b), (Lund, Nettleton, McCarthy, &
Smyth, 2012). However, this approach has a few shortcomings. A typical analysis resulted in
a large list of differentially expressed genes, giving results which were difficult to interpret.
Also, individual genes do not act alone, but work in tandem with other genes in complex
pathways. This implies that a univariate statistical analysis may inappropriately refelcts
reflects the biological reality, thus using pathways as the unit of analysis is preferable. In this
setting, a multivariate statistical model is more suitable. Some examples include the Nstatistic, a multivariate nonparametric method,(Larson & Owen, 2015)(Baringhaus & Franz,
2004) and ROAST(Wu et al., 2010), which uses multivariate linear regression to test for
differential expression. In fact, multivariate techniques have been shown to achieve higher
power

and

conserve

type

I

error

when

compared

to

aggregating

univariate

analyses(Rahmatallah, Emmert-Streib, & Glazko, 2016).
While these techniques address using the pathway as the unit of analysis, they do not
explicitly incorporate the relationship between genes in a given pathway. For RNA-seq data,
there are some gene pairs with non-negligible correlation as well a number of gene pairs with
11

negligible correlation. This is important to add such features to the data analysis and failure to
do some may lead to errors in statistical inference. Additionally, the correlation structures are
typically not simple and it is important to choose a statistical model with sufficient flexibility.
Certain models such as the multivariate negative binomial (Solis-Trapala & Farewell, 2005)
have a restrictive implied correlation structure, only allowing for positive correlation, equal
among all genes. Indeed, most multivariate parametric models for count data fall into similar
categories.
To address the concern of correlation among genes, we propose to use Generalized
Estimating Equations (GEE) (Li & Chan, 2006) (K.-L. Liang & Zeger, 1986; Wang, 2014).
In GEE, a “working” correlation structure is used, which allows for a flexible correlation
structure between the genes in a pathway. A new intermediate correlation structure is also
developed to handle a mixed correlation structure, which is more characteristic of RNA-seq
data.

Simulations are conducted to compare different correlation structures and how

correlation among genes impacts the type I error and statistical power. Also, a statistical test
for independence of genes in a pathway is formulated and simulations are used to identify the
statistical power and type I error in the presence of different correlation structures.
Using appropriate correlation matrices for a gene network helps to safeguard against
errors in statistical inference and makes a more statistically sound model.

Using an

unstructured correlation matrix may be impractical for most datasets because of the number of
parameters that need to be estimated. Often, the sample size is insufficiently large to use
unstructured and the estimates are unreliable. Alternatively, exchangeable uses only one
parameter, which may be insufficient for more complicated structure, which are more likely in
12

real datasets. An intermediate correlation, with more parameters than exchangeable and fewer
parameters than unstructured, helps to overcome these challenges in the estimation and
incorporation of appropriate correlation structures in RNA-seq data analysis.

Increased

flexibility in estimated correlation structures allows for less of a chance of a misspecified
correlation matrix. Furthermore, a general procedure for determining correlation matrices
allows researchers to customize their correlation estimation based on their dataset.
Methods
Generalized Estimating Equations (GEE)
Generalized Estimating Equations (GEE) is an estimation technique for analyzing nonnormal correlated data, for example clustered data. A gene network can be interpreted as a
cluster of genes with connections between genes denoting some correlation while unconnected
genes having approximately zero correlation.
Let 𝑦𝑦𝑖𝑖 be the gene expression measurements for each of g genes in a given gene network

for 𝑖𝑖 = 1, ⋯ , 𝑛𝑛 patient samples such that 𝑦𝑦𝑖𝑖 is a 𝑔𝑔 × 1 vector. In contrast to the typical gene

expression matrix format, this notation is for a long format where the columns of such a matrix
are stacked on top of each other. Additionally, let 𝜇𝜇𝑖𝑖 = 𝐸𝐸(𝑌𝑌𝑖𝑖 ), be the 𝑔𝑔 × 1 mean vector for

each of the g genes in a given gene network. Under this notation, 𝑦𝑦𝑖𝑖𝑖𝑖 refers to the gene

expression of sample i for gene j and similarly, 𝜇𝜇𝑖𝑖𝑖𝑖 represents the mean parameter for sample
i and gene j. In this scenario, we assume that patient samples are independent, but genes within

a gene network are correlated with one another (to some degree). Instead of using an assumed
probability distribution and deriving its likelihood, GEE uses the quasi-likelihood, which only
requires specifying the relationship between the mean and the variance. For RNA-seq data,
13

the negative binomial distribution is the most common for modeling the expression of a single
gene. We can use the same mean-variance structure as the univariate negative binomial
distribution:
𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖 � = 𝜇𝜇𝑖𝑖𝑖𝑖

(1)

2
𝑣𝑣�𝜇𝜇𝑖𝑖𝑖𝑖 � = 𝜇𝜇𝑖𝑖𝑖𝑖 + 𝜔𝜔𝜔𝜔𝑖𝑖𝑖𝑖

(2)

Where, 𝜔𝜔 represents the negative binomial dispersion parameter. Using this relationship, the
1/2

1/2

covariance matrix of 𝑦𝑦𝑖𝑖 (a 𝑔𝑔 × 𝑔𝑔 matrix) can be calculated as 𝑉𝑉𝑖𝑖 = 𝜙𝜙𝐴𝐴𝑖𝑖 𝑅𝑅𝑖𝑖 𝐴𝐴𝑖𝑖 , where 𝜙𝜙 is

a scale parameter to be estimated, 𝐴𝐴𝑖𝑖 is a 𝑔𝑔 × 𝑔𝑔 diagonal matrix with 𝑣𝑣�𝜇𝜇𝑖𝑖𝑖𝑖 � as the diagonal
elements, i.e. 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 �𝑣𝑣(𝜇𝜇𝑖𝑖1 ), 𝑣𝑣(𝜇𝜇𝑖𝑖2 ), ⋯ , 𝑣𝑣�𝜇𝜇𝑖𝑖𝑖𝑖 ��, and 𝑅𝑅𝑖𝑖 is a 𝑔𝑔 × 𝑔𝑔 matrix that represents the

“working correlation” structure, which describes the relationship between the genes within a
gene network. The correlation structure is chosen by the researcher and is “working” in the
sense that is an initial guess, which may be misspecified. Simple correlation structures such
as exchangeable (all correlation values are the same).

Alternatively, an unstructured

correlation structure, in which all correlation parameters are unique, requires a large sample
size relative to the size of the gene network (~ 30 genes per network) and is not feasible except
for very small gene networks with large sample sizes.
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Table 1: Example Correlation Structures
Correlation

Example

Structure

Matrix

Independent

Exchangeable

Unstructured

1
�0
0

1
�𝛼𝛼
𝛼𝛼

1
�𝛼𝛼21
𝛼𝛼31

Correlation

0 0
1 0�
0 1

𝛼𝛼
1
𝛼𝛼

𝛼𝛼12
1
𝛼𝛼32

Estimator

NA

𝐾𝐾

1
𝛼𝛼� = ′
� � 𝑒𝑒𝑖𝑖𝑖𝑖 𝑒𝑒𝑖𝑖𝑖𝑖
(𝑁𝑁 − 𝑝𝑝)𝜙𝜙

𝛼𝛼
𝛼𝛼 �
1

′

𝐾𝐾

𝑖𝑖=1 𝑗𝑗≠𝑘𝑘

𝑁𝑁 = � 𝑔𝑔 ∗ (𝑔𝑔 − 1)

𝛼𝛼13
𝛼𝛼23 �
1

𝛼𝛼�𝑗𝑗𝑗𝑗

𝑖𝑖=1

𝐾𝐾

1
=
� 𝑒𝑒𝑖𝑖𝑖𝑖 𝑒𝑒𝑖𝑖𝑖𝑖
(𝐾𝐾 − 𝑝𝑝)𝜙𝜙
𝑖𝑖=1

Framework for Correlation Structures
An exchangeable correlation structure represents one parameter being estimated and
the correlation between each gene pair is the same. Similarly, an unstructured correlation
structure estimates a different correlation parameter for each different gene pair. These
structures represent two extremes for correlation structures. Exchangeable structures may not
be as useful if the true correlation matrix between genes contains a mix of signs. An
unstructured correlation matrix is limited in applicability because the sample size needs to be
sufficiently larger than the number of genes in a network in order to obtain adequate estimates
of these correlations. Using an unstructured correlation for larger networks can result in an
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unstable correlation matrix, which leads to numerical divergence and consequently reduced
power.
In practice, Pearson residuals are used to estimate the individual correlation parameters.
1

For unstructured, each correlation parameter is estimated by 𝛼𝛼�𝑗𝑗𝑗𝑗 = (𝐾𝐾−𝑝𝑝)𝜙𝜙 ∑𝐾𝐾
𝑖𝑖=1 𝑒𝑒𝑖𝑖𝑖𝑖 𝑒𝑒𝑖𝑖𝑖𝑖 . In
1

contrast, exchangeable estimates its one correlation parameter as 𝛼𝛼� = (𝑁𝑁′ −𝑝𝑝)𝜙𝜙 ∑𝐾𝐾
𝑖𝑖=1 ∑𝑗𝑗≠𝑘𝑘 𝑒𝑒𝑖𝑖𝑖𝑖 𝑒𝑒𝑖𝑖𝑖𝑖
𝑁𝑁 ′ = ∑𝐾𝐾
𝑖𝑖=1 𝑔𝑔 ∗ (𝑔𝑔 − 1).

Exchangeable can be interpreted as an average of the all the

unstructured parameters. It is useful to identify a procedure for estimating intermediate
correlation structures; one with more parameters than exchangeable, but fewer than
unstructured. The main idea is to sort Pearson residuals into k quantiles and average across
these quantiles. For example, for k = 3:

1. Calculate the mean Pearson residual products 𝑒𝑒̂𝑗𝑗𝑗𝑗 =

1

𝑛𝑛

∑𝑛𝑛𝑖𝑖=1 𝑒𝑒𝑖𝑖𝑖𝑖 𝑒𝑒𝑖𝑖𝑖𝑖 .

2. Sort products into positive and negative. For each, sort into three quantiles.
3. For each of these quantiles calculate the average to get parameter estimates 𝛼𝛼�𝑚𝑚 , 𝑚𝑚 =
1, … ,6.

The result of this estimation procedure will result in six different parameters; three of which
are positive and three which are negative. Additionally, we need to map each parameter to its
correct location (gene pair) in the correlation matrix. To do this, the parameter which
minimizes the distance of each parameter and the mean Pearson residual products is selected
for that particular pair:
min|𝛼𝛼�𝑚𝑚 − 𝑒𝑒̂ |
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For k =1, this procedure reduces to the exchangeable model (an average of all the Pearson
residuals) and if k is equal to the number of off-diagonal elements, this reduces to the
unstructured model. A general procedure can be defined by sorting Pearson residual products
into k quantiles.
Estimation and Hypothesis Testing
The primary purpose of using this technique is to assess differential expression at the gene
network level. To do this, a regression model is fit with a log link function:
𝑙𝑙

log 𝜇𝜇𝑖𝑖𝑖𝑖 = 𝛽𝛽0 + 𝛽𝛽1 𝑋𝑋1 + � 𝛽𝛽𝑘𝑘 𝑋𝑋𝑘𝑘

(3)

𝑘𝑘=2

𝑋𝑋1 denotes the group for each of samples (for example, 𝑋𝑋1 might be a binary vector with zero
value denoting normal samples and one value denoting tumor samples), 𝑋𝑋𝑘𝑘 are additional

covariates which can be adjusted for. Estimating the regression coefficients will give the
differential expression �𝛽𝛽̂1 � adjusted for any additional covariates. In order to estimate the
regression coefficients, the following estimating equation should be solved:
𝑛𝑛

𝑈𝑈(𝜷𝜷) = � 𝐷𝐷𝑖𝑖𝑇𝑇 𝑉𝑉𝑖𝑖−1 (𝑌𝑌𝑖𝑖 − 𝜇𝜇𝑖𝑖 ) = 0

(4)

𝑖𝑖=1

where 𝐷𝐷𝑖𝑖 =

𝜕𝜕𝜇𝜇𝑖𝑖
𝜕𝜕𝜕𝜕

. Since 𝑉𝑉𝑖𝑖 is also a function of the parameters 𝜔𝜔 and 𝜙𝜙, these will be estimated

separately and replaced in the estimating equation with their estimated values. 𝜔𝜔 is the
negative binomial dispersion parameter and in the context of single gene RNA-seq analyses,

estimates have been developed, for example the edgeR package (McCarthy et al., 2012b;
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Robinson, McCarthy, & Smyth, 2010). The estimate of 𝜔𝜔, 𝜔𝜔
�, is obtained by taking the average

of each tagwise dispersion estimate for each gene in a given gene network. Additionally, the
scale parameter is estimated as:
𝑛𝑛

𝑔𝑔

𝑦𝑦𝑖𝑖𝑖𝑖 − 𝜇𝜇𝑖𝑖𝑖𝑖
1
𝜙𝜙� =
��
𝑁𝑁 − 𝑝𝑝
𝑖𝑖=1 𝑗𝑗=1 �𝑣𝑣�𝜇𝜇𝑖𝑖𝑖𝑖 �

(5)

𝑁𝑁 = 𝑛𝑛 ∗ 𝑔𝑔 and 𝑝𝑝 is the number of regression coefficients, 𝛽𝛽. Both 𝜔𝜔
� and 𝜙𝜙� replace 𝜔𝜔 and 𝜙𝜙

� . The covariance matrix for
in 𝑉𝑉𝑖𝑖 and the equation in (4) is solved for 𝜷𝜷, yielding estimates 𝜷𝜷

� can be calculated as:
𝜷𝜷

� � = 𝑉𝑉0−1 𝑉𝑉1 𝑉𝑉0−1
Cov�𝜷𝜷
𝑛𝑛

𝑉𝑉0 = � 𝐷𝐷𝑖𝑖𝑇𝑇 𝑉𝑉𝑖𝑖−1 𝐷𝐷𝑖𝑖

(6)

(7)

𝑖𝑖=1

𝑛𝑛

𝑉𝑉1 = � 𝐷𝐷𝑖𝑖𝑇𝑇 𝑉𝑉𝑖𝑖−1 Cov(𝑌𝑌𝑖𝑖 )𝑉𝑉𝑖𝑖−1 𝐷𝐷𝑖𝑖

(8)

𝑖𝑖=1

where Cov(𝑌𝑌𝑖𝑖 ) = 𝑟𝑟̂𝑖𝑖 𝑟𝑟̂𝑖𝑖𝑇𝑇 , 𝑟𝑟̂𝑖𝑖 = 𝑌𝑌𝑖𝑖 − 𝜇𝜇̂ 𝑖𝑖 .

� is
According to (K.-Y. Liang & Zeger, 1986), 𝜷𝜷

distributed asymptotically normal with mean 𝜷𝜷 and covariance matrix given in (6). Based on

these asymptotic results, a Wald test can be used to test for differential expression at the gene
network level:
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𝑍𝑍 =

𝛽𝛽̂

�Cov�𝛽𝛽̂ �

~ 𝑁𝑁(0, 1)

(9)

here, the test statistic is for a particular 𝛽𝛽 and the denominator represents the standard error,

which can be obtained from the corresponding element of the diagonal of the covariance
matrix. The covariates in the regression model may also be tested if these parameters are of
interest, but in general, the primary focus is 𝛽𝛽̂1, the differential expression effect.

The aforementioned procedure details how to test for differential expression for a given

gene network. For a list of gene networks, this process can be repeated multiple times,
however, additional false positives may be incurred. False discovery rates (FDRs) can be used
in lieu of the p-values obtained from the Wald test to control false positives (Benjamini &
Hochberg, 1995; Storey, 2010).
Test for Gene Set Independence
For a given gene network, researchers may be interested if the genes in a particular
gene network are correlated or are independent. Under the null hypothesis (a gene network is
independent), we expect that each pairwise correlation coefficient is approximately zero.
Formally, this leads to the null hypothesis: 𝐻𝐻0 : 𝑹𝑹 = 𝐈𝐈. In order to test this hypothesis, the
estimated correlation matrices from the expression matrix of the gene network are compared

to an estimated correlation matrix from a simulated dataset, where the underlying correlation
is zero. A dataset simulated under the null hypothesis is preferable as a comparison rather than
the identity matrix because realistically true independent gene networks may still have a small
degree of correlation and this helps not to overinflate the statistical power of the test.
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The test statistic we propose to use is the distance test, initially used to compare
correlation matrices across groups (for example, tumor versus normal) in the context of coexpression analyses(Choi & Kendziorski, 2009). For this application, the perspective is to
estimate the correlation matrix of the gene network and then compare it to the estimated
correlation matrix of a null dataset. This test statistic is:

𝑔𝑔∗(𝑔𝑔−1)

1
𝐷𝐷 = �
� (𝜌𝜌𝑖𝑖1 − 𝜌𝜌𝑖𝑖0 )2
𝑔𝑔 ∗ (𝑔𝑔 − 1)

(10)

𝑖𝑖=1

Where g is the number of genes in the gene network, 𝜌𝜌𝑖𝑖1 is a vector of the correlation
coefficients for all the gene pairs from the dataset, and 𝜌𝜌𝑖𝑖0 is the correlation vector from the

null dataset. Also, setting 𝜌𝜌𝑖𝑖0 = 0 reduces the test statistic D to the case where the identity
matrix is used under the null hypothesis. Since the test statistic does not follow a simple
distribution, p-values are obtained through the following permutation approach. Class labels
are assigned to the correlation matrix from the data and the correlation matrix from the
simulated dataset where the underlying correlation is zero. These labels are shuffled k times,
for example, k = 1,000. For each shuffle, the test statistic is calculated. The p-value is
calculated as the number of these shuffled test statistics that are greater than the observed test
statistic (non-shuffled version) divided by k.
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Numerical Studies
In order to compare the efficacy of GEE for RNA-seq data analysis and the measure
the impact correlation has on statistical inference, we conduct a simulation study. For this
simulation study, the GEE method will be compared against different correlation structures:
independence, exchangeable, intermediate, and unstructured. In the context of the GEE
method, two types of analyses are pursued: a type I error analysis and a power analysis. The
type I error analysis uses simulated data to estimate the type I error rate of each particular
method. The power analysis estimates the statistical power for each method over an array of
alternative hypotheses. Additionally, these analyses are also performed for the statistical test
of gene set independence.
Simulation of Data
For each gene network, a g x n expression matrix is generated with g genes in the given
network and n samples. The expression matrix is a matrix of counts with mean 𝝁𝝁 (a vector of
means corresponding to each individual gene in the gene network), dispersion 𝝎𝝎 (a vector of

dispersions), and R, a correlation matrix for the genes in the gene network. This expression
matrix can be generated using the following algorithm:

1. Generate data from a multivariate normal distribution with sample size n, mean
vector 0, and correlation matrix R.
2. For each column, calculate the standard normal cdf, Φ , of the data values.
3. Calculate the quantile function of the negative binomial distribution with mean
𝜇𝜇 and dispersion .
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This algorithm uses an inverse cdf technique in order to generate correlated negative binomial
random variables that has been used to generate correlated random variables for a number of
other distributions such as Poisson. This technique is attractive because of its simplicity,
relative speed, and a fairly accurate empirical correlation matrix.
Type I Error Analysis
To simulate gene networks under the null hypothesis the means are kept the same for
both groups (e.g tumor and normal, 𝝁𝝁𝒕𝒕𝒕𝒕𝒕𝒕𝒕𝒕𝒕𝒕 = 𝝁𝝁𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏).

We investigate nine different

correlation scenarios for each positive, negative, and mixed correlation structures with low,
medium, and high strength (magnitude) of correlation.

Pairwise correlation values are

generated from a uniform distribution with range according to strength of correlation. Weak
correlations are generated as U(0, 0.1), medium correlations are generated as U(0.2, 0.4), and
strong correlations are generated as U(0.5, 0.8). Correlation matrices which are not positive
definite are replaced with the nearest positive definite matrix. In the case of strong negative
correlation, a few values are chosen to be highly negative while the rest are zero. This ensures
positive definiteness while still having some highly negative values. For each of these
correlation scenarios, we simulate data for gene networks of size 10, 30, and 50 genes. For
each of these
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Table 2: Type I error rates for different GEE models.

Correlation

Independent

(+) weak

0.077

Exchangeable

Intermediate

Unstructured

(10 0.045

0.043

0.040

(30 0.053

0.051

0.047

(50 0.043

0.052

0.059

0.249

0.052

0.054

0.057

0.468

0.056

0.052

0.049

0.561

0.049

0.050

0.051

0.434

0.049

0.052

0.053

0.628

0.077

0.054

0.045

0.718

0.087

0.057

0.054

0.008

0.065

0.064

0.064

0.006

0.075

0.065

0.067

0.04

0.053

0.052

0.051

0.008

0.065

0.064

0.060

0.007

0.066

0.065

0.060

0.010

0.059

0.055

0.052

0.008

0.060

0.058

0.060

Genes)
0.150
Genes)
0.195
Genes)
(+) medium

(+) strong

(-) weak

(-) medium

(-) strong
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(mix) weak

(mix) medium

(mix) strong

0.003

0.045

0.055

0.060

0.010

0.055

0.057

0.062

0.044

0.045

0.047

0.048

0.053

0.053

0.052

0.057

0.072

0.068

0.059

0.057

0.078

0.054

0.049

0.045

0.089

0.051

0.052

0.056

0.120

0.051

0.059

0.071

0.096

0.045

0.049

0.051

0.143

0.058

0.056

0.057

0.140

0.05

0.05

0.05

datasets, type I error is estimated by the percentage of p-values < 0.05. This factorial design
helps to identify how different correlation structures and gene network size impact type I error.
When using the independence correlation structure, the type I error is not conserved.
For positive correlation, the type I error is increased, while for negative correlation, the type I
error is decreased, relative to the p-value threshold level. In the case of mixed correlations,
the type I error is increased, but by a smaller degree than for positive correlation. For both the
exchangeable and unstructured correlation structure, type I error levels are roughly conserved
for all the different correlation structures. For a gene network of larger size, the errors from
independence correlation structure are larger. For example, for positive correlation the type I
error is increased for a larger gene network, while for negative correlation the type I error is
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smaller. There is a similar pattern for mixed correlation structures. For larger gene networks,
both the exchangeable and unstructured conserve the type I error.
Power Analysis
To simulate gene networks under the alternative hypothesis, the means in one group
are larger than the other, by a multiplicative factor (e.g. tumor and normal, 𝐹𝐹𝐹𝐹 ∗ 𝝁𝝁𝒕𝒕𝒕𝒕𝒕𝒕𝒕𝒕𝒕𝒕 =

𝝁𝝁𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏, where FC is the multiplicative factor). Similar to the type I error analysis, the same
correlation structures and gene network sizes are used. Additionally, an empirical p-value

threshold is used to determine significance, to guard against inflating power from higher type
I error rates. Usually, a threshold level of 𝛼𝛼 = 0.05 is used to determine significance for pvalues. However, some methods may have more or less type I error than the 0.05 level,

implying the method is overly liberal or overly conservative. In these cases, a different
threshold value should be estimated to ensure that type I error is conserved. Let p denote the
p-value, N denote the number of tests conducted (for example, number of simulations), and 𝛼𝛼 ′

denote the new threshold value. The updated threshold level can be calculated by solving the
following equation for 𝛼𝛼 ′ :

1
𝐼𝐼(𝑝𝑝 < 𝛼𝛼 ′ ) = 𝛼𝛼
𝑁𝑁

(11)

Where 𝐼𝐼(∙) represents the indicator function. The left hand side can be interpreted as the

percentage of p-values below the threshold 𝛼𝛼 ′ . This equation can be numerically solved, for
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example, by using the function uniroot() in R. Using this new threshold, we estimate statistical
power as the percentage of p-values < 𝛼𝛼 ′ .

For each individual correlation structure, power across the different models is roughly the

same. This implies that any unadjusted power gains from independent model are mostly errors,
resulting from a greater type I error. When using the correct p-value threshold level, all of the
models will likely give similar results. However, the correct p-value threshold is unknown,
making the independence model a riskier choice than models which adjust for correlation.
Additionally, all of the models have greater power for larger gene networks. This observation
is consistent with other work on gene networks in both RNA-seq and microarrays.

Test of Gene Set Independence: Type I Error and Power
It is important to benchmark new statistical tests to evaluate their efficacy of achieving
their intended goal. To accomplish this, 1000 datasets are generated with network size 10, 30,
and 50. The test statistic D is applied to each dataset and p-values are obtained using 1000
permutations. For type I error analysis, datasets are generated under the null hypothesis (i.e.
no difference in correlation structure), while for power analysis, datasets are generated under
nine different correlation scenarios (positive, negative, and mixed; weak, medium, and strong).
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Table 3: Power analysis for different GEE models.
Correlation

Method

DE = 1.2

DE = 1.5

DE = 1.8

DE = 2

DE = 3

(+) weak

Independent

0.407 (10 genes)

0.961

1

1

1

0.679 (30)

0.998

1

1

1

0.771 (50)

1

1

1

1

0.409

0.960

1

1

1

0.657

0.998

1

1

1

0.753

1

1

1

1

0.410

0.960

1

1

1

0.669

0.999

1

1

1

0.763

1

1

1

1

0.409

0.960

1

1

1

0.608

0.998

1

1

1

0.596

0.998

1

1

1

0.209

0.679

0.935

0.985

1

0.221

0.701

0.950

1

1

0.259

0.800

0.982

1

1

0.197

0.640

0.920

0.977

1

0.202

0.691

0.927

1

1

0.213

0.659

0.918

0.975

1

0.201

0.662

0.924

0.981

1

0.207

0.697

0.941

1

1

0.210

0.699

0.949

1

1

0.180

0.628

0.913

0.975

1

0.207

0.683

0.938

1

1

0.196

0.598

0.898

0.960

1

0.204

0.503

0.797

0.894

0.998

0.152

0.427

0.682

0.793

1

0.133

0.469

0.768

0.852

1

0.125

0.393

0.684

0.801

0.993

0.105

0.309

0.587

0.745

0.990

0.094

0.272

0.487

0.614

0.975

0.123

0.402

0.701

0.823

0.996

0.111

0.423

0.756

0.856

1

0.102

0.487

0.802

0.902

1

0.120

0.353

0.658

0.796

0.993

0.127

0.37

0.666

0.777

0.995

0.107

0.343

0.575

0.678

0.914

0.534

0.997

1

1

1

0.996

1

1

1

1

1

1

1

1

1

0.531

0.997

1

1

1

0.997

1

1

1

1

1

1

1

1

1

0.532

0.998

1

1

1

0.995

1

1

1

1

1

1

1

1

1

0.517

0.997

1

1

1

0.982

1

1

1

1

Exchangeable

Intermediate

Unstructured

(+) medium

Independent

Exchangeable

Intermediate

Unstructured

(+) strong

Independent

Exchangeable

Intermediate

Unstructured

(-) weak

Independent

Exchangeable

Intermediate

Unstructured
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(-) medium

Independent

Exchangeable

Intermediate

Unstructured

(-) strong

Independent

Exchangeable

Intermediate

Unstructured

(mix) weak

Independent

Exchangeable

Intermediate

Unstructured

(mix) medium

Independent

Exchangeable

Intermediate

Unstructured

(mix) strong

Independent

1

1

1

1

1

0.710

1

1

1

1

0.996

1

1

1

1

1

1

1

1

1

0.713

1

1

1

1

0.997

1

1

1

1

1

1

1

1

1

0.716

1

1

1

1

0.998

1

1

1

1

1

1

1

1

1

0.693

1

1

1

1

0.982

1

1

1

1

0.998

1

1

1

1

0.717

1

1

1

1

0.997

1

1

1

1

0.999

1

1

1

1

0.714

1

1

1

1

0.993

1

1

1

1

0.998

1

1

1

1

0.716

1

1

1

1

0.995

1

1

1

1

0.999

1

1

1

1

0.669

1

1

1

1

0.982

1

1

1

1

0.995

1

1

1

1

0.483

0.990

1

1

1

0.875

1

1

1

1

0.973

1

1

1

1

0.480

0.990

1

1

1

0.877

1

1

1

1

0.968

1

1

1

1

0.482

0.992

1

1

1

0.879

1

1

1

1

0.973

1

1

1

1

0.454

0.985

1

1

1

0.815

1

1

1

1

0.934

1

1

1

1

0.380

0.954

1

1

1

0.791

1

1

1

1

0.907

1

1

1

1

0.382

0.948

1

1

1

0.789

1

1

1

1

0.906

1

1

1

1

0.384

0.956

1

1

1

0.792

1

1

1

1

0.913

1

1

1

1

0.443

0.943

1

1

1

0.772

1

1

1

1

0.832

1

1

1

1

0.392

0.938

1

1

1
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Exchangeable

Intermediate

Unstructured

0.689

1

1

1

1

0.707

1

1

1

1

0.396

0.940

1

1

1

0.665

1

1

1

1

0.678

1

1

1

1

0.399

0.951

1

1

1

0.672

1

1

1

1

0.692

1

1

1

1

0.400

0.955

1

1

1

0.677

1

1

1

1

0.718

1

1

1

1

Table 4: Type I error rate and power benchmarking for test of gene set independence.

10 Genes

30 Genes

50 Genes

Type I Error

0.046

0.052

0.040

(+) weak

0.114

0.334

0.655

(+) medium

1.000

1.000

1.000

(+) strong

1.000

1.000

1.000

(-) weak

0.140

0.159

0.185

(-) medium

0.512

0.433

0.653

(-) strong

0.542

0.832

0.995

(mix) weak

0.116

0.328

0.641

(mix) medium

1.000

1.000

1.000

(mix) strong

1.000

1.000

1.000
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Discussion
We have applied GEE to analyze gene networks for RNA-seq and developed a
framework for identifying intermediate correlation structures that align more closely with real
RNA-seq data. Using an independent correlation structure results in an increased type I error
when the true underlying correlation matrix contains positive correlations. Similarly, when
the true underlying correlation matrix is negative, type I error is decreased. Incorporating
correlation into the data analysis acts as a safeguard to ensure type I error is conserved. The
developed framework for estimating intermediate correlation structures allows researchers to
incorporate correlation structures of varying complexity into the data analysis. The tradeoff is
simpler correlation structures will have quicker convergence and more reliable estimation,
while more complicated structures may risk divergence or be slower to converge. These
choices should be made within the context of sample size; a larger sample size may be able to
afford a more complicated correlation structure. Using this framework, researchers are no
longer forced to choose between two extremes when incorporating correlation into the data
analysis, which leads to a more accurate model of the data.
The development and incorporation of an intermediate correlation structure unlocks the
potential of analyzing clustered data with mixed correlation structures. Typically, GEE
analyses of clustered data use an exchangeable structure due to its simplicity. This paradigm
likely exists because of its initial application to longitudinal datasets, where measurements at
follow-up times are positively correlated with one another. While the usage of a robust
variance estimator could adjust for a misspecified correlation structure post-hoc, this would be
less efficient and conceptually sound. Creating better initial guesses makes the technique more
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statistically sound and beneficial when the sample size is lower. Additionally, there are likely
other datasets with count (or other data type) outcomes which could benefit from the
intermediate correlation structure.
Another approach to modeling correlation in gene networks for RNA-seq is to use
random effects via a mixed model. Mixed models have been applied for count data in analysis
of microbiomes (X. Zhang et al., 2017). The fundamental difference between mixed models
and GEE is a difference in interpretation. Estimates from a mixed model are individual
specific, while estimates from GEE indicate the population average. Also, these estimates are
usually different, implying that they could lead to the discovery of different gene networks.
The GEE method also has some shortcomings. The numerical algorithm for fitting the
regression models can sometimes diverge leading to inaccurate estimates and inferences. We
observed that this happens when the correlation structure is misspecified, specifically for high
positive correlation; an issue that has been previously reported (Sutradhar & Das, 1999). These
divergence issues are often exacerbated for larger gene networks. Model divergence can also
occur in cases where the number of genes in a network are large relative to the sample size,
specifically for unstructured correlation. These issues limit the applicability of the method for
the purpose of analyzing RNA-seq, however, the intermediate structure attempts to mitigate
these issues. Nevertheless, there are scenarios where the usage of GEE may not be correct.
There are a couple of extensions of this particular model that researchers could pursue
in the context of RNA-seq analysis. First, we could consider the regression coefficients of
interest (𝛽𝛽) to be only positive. The individual gene coefficients are rarely all of the same

sign; many gene networks have a mix of up-regulated and down-regulated genes. This mixing
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likely shrinks the coefficient towards zero and underestimates the true coefficient. Restricting
it to only be positive may be closer to the true value. Second, methods could be developed to
average expert opinion and/or network connections with RNA-seq data. The current model
supports entering in a user-defined correlation structure, but suffers some of the same issues
as the unstructured correlation model. Incorporating this information in the estimation process
is intuitively appealing and may offer improved power.

32

Acknowledgements:
Andrew Aschenbrenner was funded by the UTHealth Innovation for Cancer Prevention
Research Training Program Pre-doctoral Fellowship (Cancer Prevention and Research
Institute of Texas grant #RP160015) and the NIH Pre-doctoral Traineeship in Biostatistics
(grant # 2T32GM074902-06). We would like to thank Stephen Daiger and Momiao Xiong for
their helpful comments on written drafts.

33

References
Baringhaus, L., & Franz, C. (2004). On a new multivariate two-sample test. Journal of
Multivariate Analysis, 88(1), 190–206. https://doi.org/10.1016/S0047-259X(03)00079-4
Benjamini, Y., & Hochberg, Y. (1995). Controlling the False Discovery Rate : A Practical
and Powerful Approach to Multiple Testing Author (s): Yoav Benjamini and Yosef
Hochberg Source : Journal of the Royal Statistical Society . Series B ( Methodological ),
Vol . 57 , No . 1 Published by : Wi. Journal of the Royal Statistical Society Series B,
57(1), 289–300.
Choi, Y., & Kendziorski, C. (2009). Statistical methods for gene set co-expression analysis.
Bioinformatics, 25(21), 2780–2786. https://doi.org/10.1093/bioinformatics/btp502
Garber, M., Grabherr, M. G., Guttman, M., & Trapnell, C. (2011). Computational methods
for transcriptome annotation and quantification using RNA-seq. Nature Methods, 8(6),
469–477. https://doi.org/10.1038/nmeth.1613
Larson, J. L., & Owen, A. B. (2015). Moment based gene set tests. BMC Bioinformatics,
16(1), 1–17. https://doi.org/10.1186/s12859-015-0571-7
Li, Y. P., & Chan, W. (2006). Analysis of longitudinal multinomial outcome data.
Biometrical Journal, 48(2), 319–326. https://doi.org/10.1002/bimj.200510187
Liang, K.-L., & Zeger, S. L. (1986). Longitudinal data analysis using generalized linear
models. Biometrika, 73(1), 13–22.
Liang, K.-Y., & Zeger, S. L. (1986). Longitudinal data analysis using generalized linear
34

models. Biometrika, 73(1), 13–22.
Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biology, 15(12), 550.
https://doi.org/10.1186/s13059-014-0550-8
Lund, S. P., Nettleton, D., McCarthy, D. J., & Smyth, G. K. (2012). Detecting differential
expression in RNA-sequence data using quasi-likelihood with shrunken dispersion
estimates. In Statistical applications in genetics and molecular biology (Vol. 11).
https://doi.org/10.1515/1544-6115.1826
Marioni, J. C., Mason, C. E., Mane, S. M., Stephens, M., & Gilad, Y. (2008). RNA-seq: an
assessment of technical reproducibility and comparison with gene expression arrays.
Genome Research, 18(9), 1509–1517. https://doi.org/10.1101/gr.079558.108
McCarthy, D. J., Chen, Y., & Smyth, G. K. (2012). Differential expression analysis of
multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids
Research, 40(10), 4288–4297. https://doi.org/10.1093/nar/gks042
Mortazavi, A., Williams, B. a, McCue, K., Schaeffer, L., & Wold, B. (2008). Mapping and
quantifying mammalian transcriptomes by RNA-Seq. Nature Methods, 5(7), 621–628.
https://doi.org/10.1038/nmeth.1226
Rahmatallah, Y., Emmert-Streib, F., & Glazko, G. (2016). Gene set analysis approaches for
RNA-seq data: Performance evaluation and application guideline. Briefings in
Bioinformatics, 17(3), 393–407. https://doi.org/10.1093/bib/bbv069
35

Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010). edgeR: a Bioconductor package
for differential expression analysis of digital gene expression data. Bioinformatics
(Oxford, England), 26(1), 139–140. https://doi.org/10.1093/bioinformatics/btp616
Solis-Trapala, I. L., & Farewell, V. T. (2005). Regression analysis of overdispersed
correlated count data with subject specific covariates. Statistics in Medicine, 24(16),
2557–2575. https://doi.org/10.1002/sim.2121
Storey, J. D. (2010). False Discovery Rates. Princeton University, Princeton, USA, (January),
1–7. https://doi.org/10.1198/016214507000000941
Sutradhar, B., & Das, K. (1999). On the Efficiency of Regression Estimators in Generalised
Linear Models for Longitudinal Data. Biometrika, 86(2), 459–465.
Wang, M. (2014). Generalized Estimating Equations in Longitudinal Data Analysis: A
Review and Recent Developments. Advances in Statistics, 2014, 1–11.
https://doi.org/http://dx.doi.org/10.1155/2014/303728
Wu, D., Lim, E., Vaillant, F., Asselin-Labat, M. L., Visvader, J. E., & Smyth, G. K. (2010).
ROAST: Rotation gene set tests for complex microarray experiments. Bioinformatics,
26(17), 2176–2182. https://doi.org/10.1093/bioinformatics/btq401
Zhang, X., Mallick, H., Tang, Z., Zhang, L., Cui, X., Benson, A. K., & Yi, N. (2017).
Negative binomial mixed models for analyzing microbiome count data. BMC
Bioinformatics, 18(1), 1–10. https://doi.org/10.1186/s12859-016-1441-7

36

JOURNAL ARTICLE
A Gene Network Analysis of Primary Breast Tumors in RNA-seq
Genetic Epidemiology
Author List: Aschenbrenner, Andrew; Loose, David; Mullen, Patricia Dolan; Fu, Yun-Xin
Abstract:
Differential expression of RNA-seq data can be useful for generating hypotheses about
genes that important in diseases. In contrast to traditional approaches, analyzing data at the
gene network level first allows researchers to incorporate correlation among genes in the gene
network into the data analysis. This helps to conserve type I error, preventing potential false
positives or false negatives. Using a breast cancer dataset from the Cancer Genome Atlas
(TCGA), gene networks are analyzed and subsequently, the individual genes from significant
networks are analyzed. This approach leads to the identification of unreported differentially
expressed genes as well as previously reported genes. Usage of a gene network approach
initially in data analysis can act as a safeguard against potential statistical inferential errors and
is advised when analyzing data.
Introduction
Breast cancer continues to be a threat to public health with new cases totaling
approximately 250,000 and 41,000 deaths per year (Siegel, Miller, & Jemal, 2016). While
there have been many research efforts dedicated to uncovering the biology of breast cancer
and how this can translate into treatments, a number of tumors remain untreatable due the lack
of complete knowledge of how different breast tumors work.

To close these gaps in

knowledge, additional investigations must be undertaken to elucidate the molecular changes
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and functions in breast tumors. One such method for doing this is through gene expression
studies.
Gene expression studies measure the amount of mRNA in different genes for a number
of samples. In the context of breast cancer, often these samples will be derived from tumor
and normal breast tissue. Comparing expression levels between tumor and normal samples
help to identify which genes may expression levels that are different between these two types
of samples, generating hypotheses about which genes may be important in tumors (a process
called differential expression analysis). Genes which are expressed differently in the two types
of samples may have a particular function that the tumor is trying to exploit. For example,
genes that control regulate cell replication may be overexpressed in tumor tissue.
Recently, gene expression studies use RNA-sequencing in order to measure the mRNA
in samples (Shendure, 2008). This technology allows for a coverage of the entire genome with
greater accuracy compared to the older technology of microarrays. While the strength of gene
expression studies is in the broad scan of a large number of genes, the large number of genes
tested for differential expression can equally be a curse. Such an analysis may be prone to
errors such as false positives or negatives because of the paradigm of testing many genes
simultaneously and ignoring structures within the data, such as correlations among genes.
While correcting for multiple comparisons helps to adjust for testing many hypotheses,
correlations among genes are typically ignored in analyses. The consequence of ignoring such
features of the data can result in a greater number of false positives or negatives (Efron &
Tibshirani, 2007), (Schaalje & Butts, 1993), (Gatti, Barry, Nobel, Rusyn, & Wright, 2010).
This means that some genes will seem to be important but further investigations will be a waste
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of resources (false positive), while some genes may be clinically relevant, but remain
undiscovered (false negatives). False negatives can be particularly nefarious because the
undiscovered connections of these genes with the disease (such as breast cancer) can prevent
the development of new treatments. To correct for these limitations, we use a gene network
approach to analyze gene expression data. A network is collection of genes that are connected
to each other. Generally, genes within a given network are hypothesized to have some amounts
of correlation with other genes in the network. Analyzing these networks instead of each gene
separately allows researchers to consider the interrelationships between genes when
conducting a differential expression analysis. Additionally, using networks instead of genes
aids in the issue of multiplicity (testing many genes at once) and leads to a balance between
fine resolutions of differential expression in genes, while still incorporating the
interdependence genes may have with one another.

Methods
The RNA-seq data used was obtained from the Cancer Genome Atlas (TCGA)
Research Network: http://cancergenome.nih.gov/.

Files were aggregated into a single

expression table with genes on the rows and samples on the columns. Corresponding patient
clinical data was downloaded and matched to the samples in the expression table for analyses
with covariates. A total of n = 96 matched samples are used in analyses, where each tumor
sample is matched on patient to a control sample. That is, each patient has a tumor sample and
a sample of normal tissue. Matched samples represent a fraction of the samples available but
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are used because of the availability of tissue sample controls and a matched design helps to
adjust for patient-to-patient heterogeneity.
Prior to data analysis, the expression data in raw count form must be normalized and
sorted into gene networks. The raw counts can take a large range of integer values, leading to
a scale problem. Additionally, gene counts are proportional to the gene length, with longer
genes having higher counts potentially biasing statistical inference. To overcome such a
problem, we transform the data through a common scaling procedure called reads per kilobase
of transcript, per million (RPKM) (Mortazavi et al., 2008):
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =

𝑛𝑛𝑔𝑔 × 109
𝑙𝑙𝑔𝑔 × 𝑁𝑁

Where 𝑛𝑛𝑔𝑔 is the number of reads mapped to gene g, 𝑙𝑙𝑔𝑔 is the length of gene g, and N is the total
number of reads mapped for a particular sample (i.e. the sequencing depth of that sample).

To analyze gene expression data at the gene network level, expression data from 20,000
genes were sorted into 200 networks through the use of Ingenuity Pathway Analysis (IPA)
(QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis)
(Kramer, Green, Pollard, & Tugendreich, 2014).

We employ Generalized Estimating

Equations (GEE) with an intermediate correlation structure (cite methods paper). Let 𝑦𝑦𝑖𝑖𝑖𝑖 be

the measurement of gene expression for 𝑖𝑖 𝑡𝑡ℎ gene and the 𝑗𝑗 𝑡𝑡ℎ sample. Here, we assume that the
patient samples are independent, but the genes within a gene network are correlated. Instead
of assumed probability distributions, only a relationship between the mean and variance is

needed for GEE. For RNA-seq data, we use the mean-variance relationship from the negative
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binomial distribution because of the popularity of the negative binomial model for individual
genes:

𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖 � = 𝜇𝜇𝑖𝑖𝑖𝑖
2
𝑣𝑣�𝜇𝜇𝑖𝑖𝑖𝑖 � = 𝜇𝜇𝑖𝑖𝑖𝑖 + 𝜔𝜔𝜔𝜔𝑖𝑖𝑖𝑖

Where 𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖 � denotes the expected value, 𝜇𝜇𝑖𝑖𝑖𝑖 is the mean, 𝑣𝑣�𝜇𝜇𝑖𝑖𝑖𝑖 � is the variance, as a function

of 𝜇𝜇𝑖𝑖𝑖𝑖 , and 𝜔𝜔 is the overdispersion parameter. The overdispersion parameter is calculated as

the mean of individual genewise dispersion paramters using edgeR (McCarthy et al., 2012b).
This type of model is beneficial because it allows for a number of different “working”
correlation structures to describe the relationship between different genes. This enables
flexibility of capturing the true relationship between genes, when other multivariate models
may have rigid correlation structures that do not work well with RNA-seq data. This method
uses an intermediate correlation structure, where six different parameters are estimated; three
being positive and three being negative. This structure is tailor-made for RNA-seq data to
model the real data’s correlation having values that are positive, negative, and close to zero.
Additionally, a regression model is fit to test the hypothesis of differential expression (i.e.
𝐻𝐻0 : 𝛽𝛽1 = 0):

𝑚𝑚

log 𝜇𝜇𝑖𝑖𝑖𝑖 = 𝛽𝛽0 + 𝛽𝛽1 𝑋𝑋1 + � 𝛽𝛽𝑘𝑘 𝑋𝑋𝑘𝑘
𝑘𝑘=2

The use of regression models over two-sample tests improves the analysis because it allows
for the incorporation of covariates into the model, given estimates of differential expression
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that are adjusted for these covariates. Based on asymptotic results (K.-L. Liang & Zeger,
1986), a Wald test is used to test for differential expression:
𝑍𝑍 =

𝛽𝛽̂

�Cov�𝛽𝛽̂ �

~ 𝑁𝑁(0, 1)

Since multiple gene networks are tested simultaneously, p-values should be converted to false
discovery rates (FDRs) to adjust for an increase in type I error.
Once a list of significantly differentially expressed gene networks is obtained, a
separate univariate analysis is run on each network. For each gene network, it is likely not all
genes in a given network are important. Using a single analysis will help to separate out the
important signals for each of these gene networks. A popular method for univariate analysis
of RNA-seq data is the R package edgeR (McCarthy et al., 2012a; Robinson et al., 2010). This
method focuses on developing a generalized linear model approach to assess differential
expression at the gene level. The gene expression level is assumed to be negative binomial
(equivalently, a Poisson-Gamma mixture) and the differential expression hypothesis is tested
via the likelihood ratio test. The dispersion parameter can be estimated using an adjusted
profile likelihood, introducing a penalty via the Fisher information. Additionally, edgeR
allows for genewise dispersion estimation, where the dispersion estimate is squeezed between
the estimate of an individual gene and the weighted average of the gene and its (physical)
neighbors. Such an estimation approach enables different genes to have different dispersion
estimates.
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Results
The data quality is assessed for each of the patient samples used in the differential expression
analysis. While TCGA has rigorous quality standards in the preparation of each sample, we
want to confirm the similarity between samples. In order to remove any effects of differences
in gene expression, normal samples were compared to other normal samples, while tumor
samples were compared to other tumor samples. QQ plots were constructed for the log of
counts per million (CPMs) for each pair of samples. The logarithm helps with the right skewed
distribution of counts (large variations between different genes for a sample), while CPMs
helps to alleviate the bias of sequencing depth. Additionally, presence of zeroes in the data
cause a kink in the graphs because of the use of pseudo-counts (adding values to zero so the
log is defined). For all pairs of samples, the QQ plots follow a straight line confirming high
similarity among samples and thus, high data quality.
Clinical data is collected for each of the patient samples and are used as covariates in the
differential expression analysis. Using clinical data is useful because it helps to explain more
of the variation between gene expression levels as opposed to only comparing tumor and
normal tissues. Clinical data was chosen by the sufficient availability of data and covariates
relevant to breast cancer. The chosen covariates are menopause status, race, vital status, stage
of cancer, age at diagnosis, and molecular subtypes. Most of the samples are white women
with stage II primary breast tumors, and generalizability of the results from the differential
expression analysis should be interpreted within this context.
Gene expression data is sorted into 200 non-overlapping gene networks, totaling
approximately 6,000 genes. The data is then fit to the following model:
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log𝜇𝜇𝑖𝑖𝑖𝑖 = 𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼 + 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 + 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 + 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 + 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 +
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 + 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 + 𝐴𝐴𝐴𝐴𝐴𝐴

To test for differential expression, a Wald test is used to test the coefficient for tumor status of
tissue is zero. P-values are transformed into false discovery rates (FDR) and gene networks
are declared significant if they fall below the FDR < 0.05 threshold. For each of these
significant

Figure 1: QQ plots for log counts per million (CPMs) for all of the genes in the RNA-seq dataset.
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Figure 2: Patient demographics for samples in the TCGA dataset
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Table 5: Results of Gene Network Analysis
Top Genes in Network

BTBD8,

SH3BGRL,

IFT46,

ERP29,

FDR

Cellular Assembly and Organization, Cell Morphology, Cellular

1.95e-302

Function and Maintenance

SRCIN1, HSPBP1
PLEKHA5,

Network Function

NCKAP1,

Cell Morphology, Cellular Development, Cellular Growth and

SHROOM2, ABL1

Proliferation

DC34, FBXO31, STON2, IL1RL1,

Cellular Assembly and Organization, Cellular Function and

DUOX2

Maintenance, Cellular Movement

ADAM9, MAPK1, PSMB8, ADAR,

Cancer, Dermatological Diseases and Conditions, Hereditary

ERCC1

Disorder

PEG3, HSD17B2, ID3, APC,

Embryonic Development, Organismal Development, Tissue

GALNT6

Development

SP5,

ZP1,

CRTC2,

HIVEP2,

MYH16,

GOLGA4,

Endocrine

System

Disorders,

8.22e-08

Organ

1.03e-07

Hereditary Disorder, Neurological Disease, Organismal Injury

8.96e-06

PGAM5,

HERC2,

DNA Replication, Recombination, and Repair, Cell Cycle,

UBE3A, PMS1

Cellular Assembly and Organization

PRKCE, NEFL, DPP6, ATL1,

Cellular Assembly and Organization, Cellular Compromise,

NRK

Cellular Function and Maintenance

TYROBP,

1.14e-11

and Abnormalities

ZNF292, NUDT13
RASSF3,

Morphology,

1.02e-13

Morphology

IQSEC1
DPYSL4,

Cell

8.85e-92

EEF1A1,

RPS18, SIRPB1

TNFSF13,

Cancer, Cell Death and Survival, Organismal Injury and
Abnormalities
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2.75e-05

2.77e-05

5.70e-05

gene networks, a single gene analysis is performed using the ‘edgeR’ package. For each gene
in a gene network, FDRs are calculated and only genes with FDR < 0.05 are kept.
Significant genes are scrutinized for biological significance by using PubMed to search
for each gene in conjunction with breast cancer. Among the top 10 genes, 4 have no citations,
while 6 have one or more citations. This implies that the data analysis method finds a mix of
genes with known changes in gene expression as well genes with unreported changes in gene
expression. These unreported genes include BTBD8, IFT46, PLEKHA5, and SHROOM2. A
full list of the significant gene networks and the associated significant single genes is available
in the appendix.
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Table 6: Single gene analysis of statistically significant gene networks.

Gene

Log Fold

FDR

Citations

Change
BTBD8

2.68

8.83e-08

0

SH3BGRL

-2.16

2.51e-07

1

IFT46

-1.93

2.60e-05

0

SRCIN1

-1.54

5.90e-04

9

HSPBP1

1.15

1.56e-02

1

PLEKHA5

3.06

4.75e-11

0

ERP29

-2.54

1.95e-08

15

NCKAP1

2.02

4.79e-06

4

SHROOM2

-1.99

4.79e-06

0

ABL1

1.79

3.11e-05
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Discussion
We have successfully analyzed RNA-seq gene expression data from patients with
primary breast tumors using a gene network analysis that directly incorporates correlation
among genes within a gene network. Additionally, we used a popular R package for single
gene analysis, edgeR, to identify the differences between genes within the top networks. This
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novel analysis led to identification of genes previously unidentified to be differentially
expressed in breast cancer patients and helps provide more evidence for differential expression
of other genes which have already been identified in the literature.
Using a novel gene network approach we are able to identify gene networks and genes
within those networks that help researchers learn more about new roles in breast cancer. The
top network helps uncover a previously unknown gene in breast cancer and its possible
function in the tumor process. Additionally, using the network perspective we are able to offer
a more complete story on genes that whose function are already established. Network analyses
can lead to more information than more traditional analyses. From these results, we suggest
that a network analysis such as the one used in this article be used in for future RNA-seq
datasets.
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CONCLUSION
This dissertation has developed a statistical methodology for analyzing gene networks
in RNA-seq data. In this approach, we propose to analyze networks as the unit of choice in
contrast to a single gene, which is the current standard. Such an approach is useful because it
directly incorporates correlation between genes within a network into hypothesis testing for a
differential expression analysis. This will help to avoid false positives and false negatives
when analyzing RNA-seq data, allowing researcher more precise information with which they
can follow-up these hypotheses in laboratory settings. This will lead to a greater understanding
of breast cancer (or other diseases or condition that wish to be studied) and this knowledge
may provide the basis of investigations into new therapies.
I proposed using generalized estimating equations (GEE) for analyzing gene networks
from RNA-seq data.

This approach allows for researchers to directly incorporate the

correlation between genes in a gene network into the data analysis. Additionally, a framework
for estimating correlation structures is developed to identify correlation structures with varying
degrees of complexity. This allows researchers to customize the correlation matrix to be
incorporated in the data analysis, relative to sample size and gene network size. A Wald test
is used to test hypotheses and multiple hypotheses are adjusted via false discovery rates.
Using a simulation algorithm to generate data from a correlated negative binomial
distribution, data is simulated for different correlation structures under both the null hypothesis
of no difference in the mean and the alternative hypothesis of difference in the mean. Different
assumed correlation structures were used in analyzing simulated data including independent,
exchangeable, intermediate (six parameters), and unstructured. In the presence of correlation,
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using an independent correlation structure increases the type I error for positive correlation or
decreases the type I error for negative correlation, relative to the significance threshold level.
On the other hand, methods incorporating correlation conserved type I error. This particular
method can be seen as a safeguard against type I errors.
Using this technique, 200 networks from a 96 sample breast cancer dataset from the
Cancer Genome Atlast (TCGA) Research Network (http://cancergenome.nih.gov/) were
analyzed. Networks with a FDR < 0.05 were kept and ranked according to smallest FDR. A
single gene analysis was then conducted on each of these networks via edgeR and the top genes
are reported. Among the top ten genes, four were unreported, while six had previously been
reported in the literature. The unreported genes include BTBD8, IFT46, PLEKHA5, and
SHROOM2. The reported genes include SH3BGRL, SRCIN1, HSPB1, ERP29, NCKAP1, and
ABL1. The mix of unreported and reported differentially expressed genes implies that this
study generates new hypotheses as well as providing additional evidence for existing
hypotheses about the genetic etiology of primary breast tumors. This study as well as future
gene expression studies help to create a more complete picture of gene functions in relation to
primary breast tumors.
The statistical method presented here should be viewed as a supplementary method to
statistical methods for RNA-seq gene expression. It provides a different perspective of the
data which can lead to previously unidentified gene networks and genes within those networks.
However, this method is not uniformly superior to other methods tested. With many methods
for assessing differential expression in RNA-seq, researchers should probably use many
methods to analyze their data. Each method gives a different perspective, which can lead to
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new insights. Also, critically thinking about the parameters of a researcher’s data (sample size,
expected fold change, number of tests conducted, etc.) may impact the results and using
methods that fit datasets may improve quality of the results.
This method also has some limitations. First, the networks gathered from IPA may not
be the “true” networks. One reason for this is technical: a user cannot upload the entire list of
the human genome onto IPA’s server at one time, so networks may be incomplete. Also, these
networks reflect the experimental literature and it cannot include what is not known. Using
networks as the unit of choice force a tradeoff when interpreting the results. Fewer hypotheses
are tested, while the researcher gives up the specificity of which gene is differentially
expressed.

Consequently, a differentially expressed network may contain equivalently

expressed genes or some genes that up-regulated with some genes that are down-regulated.
This may lead to unexpected results and may limit the interpretability of the estimated log fold
change.
While the focus of this dissertation was on GEE and marginal models (a population
averaged approach), there are other methodological approaches that could be pursued. A
mixed modeling approach could be considered under the generalized linear mixed model
(GLMM) framework. Using random effects might be more comparable and useful when
looking at single gene techniques. Examples of these techniques could be mixed Poisson,
mixed Negative Binomial, and Dirichlet Negative Multinomial. Also, since networks often
contain both up-regulated and down-regulated genes it may be more useful to estimate total
magnitudes rather than coefficients with signs. This would be a measure of the networks total
disruption rather than making statements about whether it’s overexpressed or underexpressed.
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The networks used in this dissertation were derived from IPA but genes could be
organized in different ways which could give different results. For example, using gene
ontologies (GOs). There are a number of ways to sort genes into networks, but it isn’t clear
which is superior. Analyses could be conducted using many methods of gene sorting. When
using networks for the analyses the overall structure and connectedness of the network was
ignored. Incorporating this network structure into correlation estimation (in conjunction with
estimates from the data) could improve performance of the technique. Additionally, this
technique is general and can be used on different RNA-seq datasets. In particular, analyzing
the gene expression of metastatic breast cancer samples may be useful, though there are much
fewer samples. RNA-seq datasets of metastatic cancer samples are also available from the
Cancer Genome Atlas (TCGA) Research Network: http://cancergenome.nih.gov/.
RNA-seq data continues to be a challenge to analyze in a faithful manner. The large
number of genes, samples, and complex systems with which genes interact with each other
makes it difficult to test for differential expression while including these complicating features.
Correlation among these genes is important, as noted by many researchers, and new insights
can be gleaned when incorporating such features. One of the reasons why progress on cancer
therapies has been relatively stunted may very well be the oversimplification of data analyses.
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APPENDICES
Appendix A: Gene Network and Single Gene Analysis Results

Gene Network Results Table
Top Genes in Network

Network Function

Network
FDR

BTBD8, SH3BGRL,
IFT46, SRCIN1, HSPBP1
PLEKHA5, ERP29,
NCKAP1, SHROOM2,
ABL1
CDC34, FBXO31, STON2,
IL1RL1, DUOX2
ADAM9, MAPK1, PSMB8,
ADAR, ERCC1
PEG3, HSD17B2, ID3,
APC, GALNT6
SP5, ZP1, CRTC2,
HIVEP2, IQSEC1
DPYSL4, MYH16,
GOLGA4, ZNF292,
NUDT13
RASSF3, PGAM5,
HERC2, UBE3A, PMS1
PRKCE, NEFL, DPP6,
ATL1, NRK
TYROBP, EEF1A1,
TNFSF13, RPS18, SIRPB1

Cellular Assembly and Organization, Cell
Morphology, Cellular Function and Maintenance

1.95e-302

Cell Morphology, Cellular Development, Cellular
Growth and Proliferation

8.85e-92

Cellular Assembly and Organization, Cellular
1.02e-13
Function and Maintenance, Cellular Movement
Cancer, Dermatological Diseases and Conditions,
1.14e-11
Hereditary Disorder
Embryonic Development, Organismal Development,
8.22e-08
Tissue Development
Cell Morphology, Endocrine System Disorders,
1.03e-07
Organ Morphology
Hereditary Disorder, Neurological Disease,
Organismal Injury and Abnormalities

DNA Replication, Recombination, and Repair, Cell
Cycle, Cellular Assembly and Organization
Cellular Assembly and Organization, Cellular
Compromise, Cellular Function and Maintenance
Cancer, Cell Death and Survival, Organismal Injury
and Abnormalities
Skeletal and Muscular Disorders, Cellular Assembly
QPCT, UBAP2L, PBLD,
and Organization, Cellular Function and
NNAT, KRT19
Maintenance
BRWD1, SUPT3H, EID3, Cellular Function and Maintenance, Cell Signaling,
RPUSD4, MED22
Gene Expression
PDLIM7, NOC4L,
RNA Post-Transcriptional Modification, Connective
DNAH14, SSSCA1,
Tissue Disorders, Developmental Disorder
DNAH6
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8.96e-06
2.75e-05
2.77e-05
5.70e-05
8.51e-05
1.88e-04
2.21e-04

Top Genes in Network

Network Function

Cellular Movement, Cancer, Organismal Injury and
Abnormalities
Cell Signaling, Nucleic Acid Metabolism, Small
Molecule Biochemistry
Cellular Function and Maintenance, Hematological
HLA-C, ZNF81, VIPR1,
System Development and Function, Cell Death and
TAPBP, HLA-A
Survival
Dermatological Diseases and Conditions,
ZNF330, MEOX1,
Organismal Injury and Abnormalities, Cell Death
CLASP1, WNT7A, IL17C
and Survival
FKBP15, NXNL1,
Developmental Disorder, Hereditary Disorder,
NANOS1, GRAMD4,
Organismal Injury and Abnormalities
COMMD7
Cell-To-Cell Signaling and Interaction, Cellular
VPS26A, ANXA6, RBP3,
Movement, Hematological System Development
GPR161, LTB4R
and Function
LRRC1, MAD2L2, POLK, Cancer, Endocrine System Disorders,
DAAM1, RAB31
Gastrointestinal Disease
FLII, NCOA2, CBX6,
Lipid Metabolism, Small Molecule Biochemistry,
RBP5, STAR
Endocrine System Disorders
LGALS9C, FCER2, CD40, Cancer, Hematological Disease, Immunological
PRDM1, MANF
Disease
MMP13, ESCO2, SMAD3, Cancer, Organismal Injury and Abnormalities,
MYOF, KDR
Cardiovascular System Development and Function
NASP, KANK2, ADARB2, Protein Degradation, Protein Synthesis, Cellular
PSMD11, PSMD4
Assembly and Organization
RPS8, C11orf58, TUFM, Cancer, Cell Death and Survival, Organismal Injury
FAU, HBB
and Abnormalities
ZNF333, CRYZL1,
Connective Tissue Disorders, Developmental
CAPN6, C12orf4, CAPN3 Disorder, Hereditary Disorder
Cellular Assembly and Organization, Cellular
NAT10, STAU1, ZNF592,
Function and Maintenance, Dermatological Diseases
OVOL1, IPO4
and Conditions
DSTN, RAPH1,
Cellular Assembly and Organization, Cellular
HEATR5B, MYO1D,
Function and Maintenance, Cell Morphology
SLC45A3
CENPO, PHF6, H2AFZ, Cellular Assembly and Organization, DNA
HIST1H2BA, APLF
Replication, Recombination, and Repair, Cell Cycle
CCL3, VCL, ATG7,
ATG4B, EGF
PDCD6, CALCB,
MDGA2, CALCRL, EIF3G
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Network
FDR
6.92e-04
9.36e-04
1.23e-03
1.23e-03
2.05e-03
2.05e-03
2.22e-03
3.09e-03
3.12e-03
5.00e-03
5.54e-03
5.56e-03
1.08e-02
1.17e-02
1.17e-02
1.42e-02

Top Genes in Network

Network Function

Cardiovascular System Development and Function,
Organ Development, Organ Morphology
Post-Translational Modification, Protein
Degradation, Cell Morphology
Lipid Metabolism, Molecular Transport, Small
Molecule Biochemistry
Cardiac Arteriopathy, Cardiovascular Disease,
Organismal Injury and Abnormalities
Hematological System Development and Function,
Immune Cell Trafficking, Inflammatory Response
Amino Acid Metabolism, Small Molecule
Biochemistry, Vitamin and Mineral Metabolism
RNA Post-Transcriptional Modification, RNA
Damage and Repair, Molecular Transport
Amino Acid Metabolism, Post-Translational
Modification, Small Molecule Biochemistry
Cellular Growth and Proliferation, Cardiovascular
YWHAB, C3AR1, SMAD2,
System Development and Function, Cardiovascular
RLIM, SKI
Disease
Cardiovascular Disease, Cardiovascular System
ZFP64, GNL2, DLEU7,
Development and Function, Nervous System
CCL22, NME1
Development and Function
NOD2, KDELR1,
Connective Tissue Disorders, Hereditary Disorder,
SNRNP40, ATF7, SELE
Inflammatory Disease
TGS1, GOLPH3, YARS2, Hereditary Disorder, Neurological Disease,
MRPL40, NAALADL2
Organismal Injury and Abnormalities
CD8B, CD8A, ITGB7,
Cellular Assembly and Organization, Cell Signaling,
CDC42SE1, MX2
Cell-mediated Immune Response
NLGN4X, EMILIN2,
Cell Death and Survival, Cancer, Organismal Injury
HRH1, OTUB2, NME4
and Abnormalities
Cell Death and Survival, Skeletal and Muscular
SFTPA1, RPS7, SIRPA,
System Development and Function, Cell
PAX4, EEF2K
Morphology
Cell-To-Cell Signaling and Interaction,
RASSF2, JAG2, TLR5,
Hematological System Development and Function,
FZD2, RIN1
Immune Cell Trafficking
CEP170, PRKD1,
CXorf21, MYH6, STEAP1
TRIM5, RASGRP1,
KEAP1, PPME1, JUNB
NR1H4, PLAA, KCNJ2,
TADA3, DLEU2
ITGB6, CACNA1C,
OBSCN, PTPRA, HAX1
COL12A1, IL1RL2,
S1PR2, DUOX1, MAML1
TYRP1, RSPO3, FCHO2,
TM9SF3, TFE3
CSTF1, CSTF2, ZNF502,
GSPT1
ZNF398, RRP1, RNH1,
NR0B1, JMJD4
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Network
FDR
1.78e-02
1.98e-02
1.98e-02
2.00e-02
2.00e-02
2.16e-02
2.16e-02
2.48e-02
2.52e-02
2.85e-02
3.11e-02
3.22e-02
3.27e-02
3.44e-02
3.52e-02
4.05e-02

Top Genes in Network

Network Function

Network
FDR

FOXC1, PBX1,
HNRNPA2B1, SFI1,
LETM2

Cell Cycle, Cellular Assembly and Organization,
Embryonic Development

4.05e-02

Single Gene Analysis Results
Gene
BTBD8
SH3BGRL
IFT46
SRCIN1
HSPBP1
PLEKHA5
ERP29
NCKAP1
SHROOM2
ABL1
CDC34
FBXO31
STON2
IL1RL1
DUOX2
ADAM9
MAPK1
PSMB8
ADAR
ERCC1
PEG3
HSD17B2
ID3
APC
GALNT6
SP5
ZP1
CRTC2

logFC FDR
2.68 1.00e-07
-2.16 3.00e-07
-1.93 2.60e-05
-1.54 5.90e-04
1.15 1.56e-02
3.06 0.00e+00
-2.54 0.00e+00
2.02 4.80e-06
-1.99 4.80e-06
1.79 3.11e-05
3.54 0.00e+00
-1.71 4.47e-05
-1.80 4.86e-05
1.93 1.01e-04
-1.70 1.01e-04
-6.41 0.00e+00
2.91 0.00e+00
-2.17 0.00e+00
2.38 2.00e-07
2.23 3.00e-07
-5.90 0.00e+00
-4.17 0.00e+00
-2.27 1.20e-06
1.66 1.09e-05
1.89 3.79e-05
-7.02 0.00e+00
4.42 0.00e+00
-3.16 0.00e+00
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Gene
HIVEP2
IQSEC1
DPYSL4
MYH16
GOLGA4
ZNF292
NUDT13
RASSF3
PGAM5
HERC2
UBE3A
PMS1
PRKCE
NEFL
DPP6
ATL1
NRK
TYROBP
EEF1A1
TNFSF13
RPS18
SIRPB1
QPCT
UBAP2L
PBLD
NNAT
KRT19
BRWD1
SUPT3H
EID3
RPUSD4
MED22
PDLIM7
NOC4L
DNAH14

logFC FDR
-2.74 1.00e-07
-1.79 1.14e-03
-8.12 0.00e+00
-5.84 0.00e+00
-4.71 0.00e+00
-3.28 0.00e+00
-2.14 4.61e-05
-7.29 0.00e+00
-2.95 0.00e+00
2.11 1.20e-06
-1.57 3.78e-04
1.43 1.14e-03
-4.16 0.00e+00
3.90 0.00e+00
-2.87 0.00e+00
-2.71 0.00e+00
-2.46 0.00e+00
-9.10 0.00e+00
-6.20 0.00e+00
-3.46 0.00e+00
-1.61 8.02e-04
-1.62 1.07e-03
-5.93 0.00e+00
4.08 0.00e+00
-3.39 0.00e+00
2.22 1.90e-06
1.92 1.01e-05
2.02 6.20e-06
1.92 1.25e-02
-1.25 1.65e-02
1.29 3.90e-02
1.07 4.90e-02
-4.45 0.00e+00
2.09 8.30e-06
1.35 3.18e-03
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Gene
SSSCA1
DNAH6
CCL3
VCL
ATG7
ATG4B
EGF
PDCD6
CALCB
MDGA2
CALCRL
EIF3G
HLA-C
ZNF81
VIPR1
TAPBP
HLA-A
ZNF330
MEOX1
CLASP1
WNT7A
IL17C
FKBP15
NXNL1
NANOS1
GRAMD4
COMMD7
VPS26A
ANXA6
RBP3
GPR161
LTB4R
LRRC1
MAD2L2
POLK

logFC FDR
1.31 6.19e-03
-1.25 8.18e-03
-7.18 0.00e+00
-3.31 0.00e+00
2.35 2.00e-06
1.49 3.09e-05
1.78 7.26e-04
2.52 1.00e-07
2.49 2.20e-06
-1.90 1.09e-05
1.94 1.09e-05
2.21 1.09e-05
-3.47 0.00e+00
-2.85 2.00e-07
2.79 7.00e-07
2.72 1.20e-06
-2.42 2.40e-06
-6.45 0.00e+00
-4.88 0.00e+00
-1.74 5.47e-05
-2.30 7.86e-05
-2.23 1.89e-04
-3.37 0.00e+00
3.09 0.00e+00
-2.73 5.00e-07
2.06 2.70e-06
-2.17 1.86e-05
-6.62 0.00e+00
2.62 0.00e+00
2.27 1.00e-07
1.67 1.54e-04
1.65 1.54e-04
-5.93 0.00e+00
-5.99 0.00e+00
-2.16 2.70e-04
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Gene
DAAM1
RAB31
FLII
NCOA2
CBX6
RBP5
STAR
LGALS9C
FCER2
CD40
PRDM1
MANF
MMP13
ESCO2
SMAD3
MYOF
KDR
NASP
KANK2
ADARB2
PSMD11
PSMD4
RPS8
C11orf58
TUFM
FAU
HBB
ZNF333
CRYZL1
CAPN6
C12orf4
CAPN3
NAT10
STAU1
ZNF592

logFC FDR
1.36 3.03e-03
-1.26 1.12e-02
-5.87 0.00e+00
2.04 2.10e-06
1.69 2.24e-04
2.05 3.96e-04
1.59 6.40e-04
-3.05 0.00e+00
2.86 0.00e+00
-3.38 1.00e-07
-2.65 1.00e-07
1.21 1.12e-02
-7.47 0.00e+00
-2.58 5.00e-07
1.86 2.80e-06
-2.24 8.40e-06
-2.02 2.05e-04
-5.88 0.00e+00
2.38 6.00e-07
2.01 1.64e-05
1.61 2.40e-05
1.80 4.32e-04
-1.99 4.42e-05
1.52 9.51e-04
-1.54 6.65e-03
1.51 7.38e-03
-1.56 8.95e-03
-5.76 0.00e+00
-6.42 0.00e+00
4.06 0.00e+00
2.71 1.00e-07
2.19 6.50e-06
-6.40 0.00e+00
-6.58 0.00e+00
-3.99 0.00e+00
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Gene
OVOL1
IPO4
DSTN
RAPH1
HEATR5B
MYO1D
SLC45A3
CENPO
PHF6
H2AFZ
HIST1H2BA
APLF
CEP170
PRKD1
CXorf21
MYH6
STEAP1
TRIM5
RASGRP1
KEAP1
PPME1
JUNB
NR1H4
PLAA
KCNJ2
TADA3
DLEU2
ITGB6
CACNA1C
OBSCN
PTPRA
HAX1
COL12A1
IL1RL2
S1PR2

logFC FDR
-3.38 0.00e+00
2.08 9.30e-04
-7.11 0.00e+00
-4.22 0.00e+00
1.54 2.65e-05
1.76 6.10e-05
2.24 6.10e-05
3.49 0.00e+00
-2.67 5.00e-07
2.42 1.10e-06
2.45 2.10e-06
1.90 8.00e-06
-4.32 0.00e+00
-3.75 0.00e+00
3.36 0.00e+00
1.84 5.00e-06
-2.04 2.20e-05
-5.00 0.00e+00
2.27 6.30e-06
2.19 7.30e-06
-2.01 3.33e-05
-1.73 3.33e-05
-4.61 0.00e+00
-3.73 0.00e+00
-3.92 0.00e+00
2.14 1.10e-06
-1.98 1.09e-04
-6.12 0.00e+00
3.37 0.00e+00
2.00 1.20e-06
-1.93 6.50e-06
-2.14 1.01e-04
1.97 5.40e-06
2.21 5.90e-06
1.60 3.95e-03
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Gene
DUOX1
MAML1
TYRP1
RSPO3
FCHO2
TM9SF3
TFE3
CSTF1
CSTF2
ZNF502
GSPT1
ZNF398
RRP1
RNH1
NR0B1
JMJD4
YWHAB
C3AR1
SMAD2
RLIM
SKI
ZFP64
GNL2
DLEU7
CCL22
NME1
NOD2
KDELR1
SNRNP40
ATF7
SELE
TGS1
GOLPH3
YARS2
MRPL40

logFC FDR
-1.36 3.95e-03
1.30 3.95e-03
-7.50 0.00e+00
-5.87 0.00e+00
-5.54 0.00e+00
-5.74 0.00e+00
-6.16 0.00e+00
-2.16 8.00e-07
-1.93 1.78e-05
1.37 4.28e-03
1.24 6.95e-03
-5.34 0.00e+00
-3.53 0.00e+00
2.57 0.00e+00
-2.08 1.40e-06
2.03 1.84e-05
-4.92 0.00e+00
-3.28 0.00e+00
2.10 1.40e-06
1.65 2.37e-04
-1.83 2.37e-04
-3.82 0.00e+00
-3.55 0.00e+00
-3.49 0.00e+00
2.56 1.00e-07
2.41 7.00e-07
2.99 0.00e+00
2.90 0.00e+00
2.77 0.00e+00
2.11 8.00e-07
-2.37 8.00e-07
-5.18 0.00e+00
5.35 0.00e+00
-2.30 7.80e-06
-1.84 1.19e-04
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Gene
logFC FDR
NAALADL2 -1.47 4.89e-04
CD8B
-8.01 0.00e+00
CD8A
-7.47 0.00e+00
ITGB7
-6.65 0.00e+00
CDC42SE1 -4.16 0.00e+00
MX2
-3.44 0.00e+00
NLGN4X
-5.70 0.00e+00
EMILIN2
-5.35 0.00e+00
HRH1
2.03 5.00e-05
OTUB2
-1.59 5.78e-04
NME4
1.62 6.97e-04
SFTPA1
-2.79 2.79e-05
RPS7
-2.00 5.27e-04
SIRPA
-1.20 1.20e-02
PAX4
1.19 1.20e-02
EEF2K
1.19 1.21e-02
RASSF2
-6.10 0.00e+00
JAG2
-3.88 0.00e+00
TLR5
-3.07 0.00e+00
FZD2
-3.27 0.00e+00
RIN1
-3.44 0.00e+00
FOXC1
-1.76 1.94e-03
PBX1
1.67 1.94e-03
HNRNPA2B1 1.29 8.31e-03
SFI1
-1.39 8.31e-03
LETM2
1.31 8.31e-03
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